This effectively limits the applications of mammalian hepcidin mostly to the treatment of iron disorders, by targeting the hepcidin/ferroportin axis, since its use in infections would have a severe impact in several iron related parameters, with negative consequences to the host. This evidence concerns the gene SLC40A1 and infection.